EUVIMEDEUVIMED entdecken
Crossref

Complement augments antibody neutralization of SARS-CoV-2 variants

Martin Jungbauer-Groznica iD, Pierre Rosenbaum iD, Isabelle Staropoli iD, Florence Guivel-Benhassine iD, Pierre-Henri Commere iD, Tom Perisse iD, Lily Bruyère iD, Aura Fantin Rengifo, Alejandro De Cruz iD, Andrea Cottignies-Calamarte iD, Sabina Andreu iD, Laurent Hocqueloux iD und 14 weitere

Science Translational Medicine · 22.07.2026 · 18 (859)

DOI: 10.1126/scitranslmed.aec6027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 22.07.2026. Verfasst von Martin Jungbauer-Groznica und 25 weiteren Autor:innen. Beteiligte Einrichtung: Antiviral Activities of Antibodies Group, Institut Pasteur, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Neutralizing, Antibodies, Viral, Complement System Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Hospices Civils de Lyon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complement system is a major effector system of the humoral immune response, but its capacity to cooperate with antibodies to inhibit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a host remains poorly characterized. Here, we combined authentic virus neutralization, antibody engineering, and single viral particle analysis by flow virometry to show that complement enhances antibody neutralization of SARS-CoV-2. Addition of complement increased neutralization titers of sera from convalescent individuals ( n = 14), vaccinated individuals ( n = 15), and individuals with hybrid immunity ( n = 15) against D614G, BA.1, XBB.1.5, and JN.1 variants by up to 42-fold. D614G and BA.1 displayed a high level of neutralization, which was only slightly improved by adding complement. Conversely, neutralization of XBB.1.5 and JN.1 was weak but strongly enhanced by complement. Among the 32 JN.1 nonneutralizers, 22 regained detectable neutralization in the presence of complement. The enhancement mainly relied on cross-reactive anti-S2 antibodies, but monoclonal antibodies targeting the receptor binding domain and N-terminal domain could also be augmented. Viral inhibition required antibody Fc hexamerization, C1q recruitment, and C3 deposition, but it was independent of the membrane attack complex formed by C9. Consistently, complement components were deposited at the surfaces of viral particles with no detectable virolysis. In sera from individuals with severe COVID-19, both complement-mediated neutralization and anti-S2 antibody levels were associated with improved survival. Overall, our data show that complement potentiates the ability of antispike antibodies to neutralize immune-evasive SARS-CoV-2 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralComplement System ProteinsCOVID-19HumansNeutralization TestsAntibodies, MonoclonalAnimalsSpike Glycoprotein, Coronavirus

Substanzen

Antibodies, NeutralizingAntibodies, ViralComplement System ProteinsAntibodies, MonoclonalSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Antiviral Activities of Antibodies Group, Institut Pasteur, Université Paris Cité, Paris, France.
  • Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.
  • Humoral Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
  • Flow Cytometry Platform, Institut Pasteur, Université Paris Cité, Paris, France.
  • International Centre of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
  • Unité Mixte de Recherche Hospices Civils de Lyon-bioMérieux, Pierre-Bénite, France.

ORCID-Profile: Martin Jungbauer-Groznica, Pierre Rosenbaum, Isabelle Staropoli, Florence Guivel-Benhassine, Pierre-Henri Commere, Tom Perisse, Lily Bruyère, Alejandro De Cruz, Andrea Cottignies-Calamarte, Sabina Andreu, Laurent Hocqueloux, Cyril Planchais, Michael White, Sophie Novault, Sophie Trouillet-Assant, Nicolas de Prost, Martin Killian, Stéphane Paul, Olivier Schwartz, Hugo Mouquet, Timothée Bruel

Förderung

  • Agence Nationale de la Recherche
  • Hospices Civils de Lyon

Zitieren

APA

Jungbauer-Groznica, M., Rosenbaum, P., Staropoli, I., Guivel-Benhassine, F., Commere, P. H., Perisse, T., Bruyère, L., Rengifo, A. F., De Cruz, A., Cottignies-Calamarte, A., Andreu, S., Hocqueloux, L., Prazuck, T., Planchais, C., White, M., Novault, S., Trouillet-Assant, S., SEVARVIR investigators, Fourati, S., …, & SEVARVIR Investigators (2026). Complement augments antibody neutralization of SARS-CoV-2 variants. Science Translational Medicine, 18(859). https://doi.org/10.1126/scitranslmed.aec6027

Vancouver

Jungbauer-Groznica M, Rosenbaum P, Staropoli I, Guivel-Benhassine F, Commere PH, Perisse T, et al. Complement augments antibody neutralization of SARS-CoV-2 variants. Science Translational Medicine. 2026;18(859). doi:10.1126/scitranslmed.aec6027

BibTeX
@article{JungbauerGroznica2026,
  author = {Jungbauer-Groznica, Martin and Rosenbaum, Pierre and Staropoli, Isabelle and Guivel-Benhassine, Florence and Commere, Pierre-Henri and Perisse, Tom and Bruyère, Lily and Rengifo, Aura Fantin and De Cruz, Alejandro and Cottignies-Calamarte, Andrea and Andreu, Sabina and Hocqueloux, Laurent and Prazuck, Thierry and Planchais, Cyril and White, Michael and Novault, Sophie and Trouillet-Assant, Sophie and SEVARVIR investigators, SEVARVIR investigators and Fourati, Slim and de Prost, Nicolas and Killian, Martin and Paul, Stéphane and Schwartz, Olivier and Mouquet, Hugo and Bruel, Timothée and SEVARVIR Investigators, SEVARVIR Investigators},
  title = {Complement augments antibody neutralization of SARS-CoV-2 variants},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {859},
  doi = {10.1126/scitranslmed.aec6027}
}
Kostenlos starten →